查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632628

體內 CRO 市場規模、佔有率、趨勢分析報告：按模型類型、按模式、按適應症、按 GLP 類型、按地區、細分市場預測，2025-2030 年

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

體內 CRO 市場成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年，全球 In Vivo CRO 市場規模將達到 79.6 億美元，2025 年至 2030 年複合年成長率為 8.13%。

新興國家醫藥市場的成長、對多種體內細胞療法的強勁需求、材料科學的快速發展以及藥物-器械組合的複雜性正在推動該地區的服務需求。此外，體內臨床前和臨床研究的增加、監管部門的核准、市場參與企業服務的擴展以及各種疾病負擔都對市場收益做出了貢獻。此外，新興經濟體增加低成本臨床前和臨床服務外包是支持體內 CRO 市場成長的關鍵因素之一。

同樣，越來越多的藥品境外外包到新興國家也創造了龐大的市場需求。已開發國家的預算審查、價格壓力和報銷制度的變化是預計印度和中國等新興國家藥品贊助商更多採用成本控制措施的一些關鍵因素。在新興國家，將臨床前體內服務等開發服務外包給合約服務供應商預計將增加對品質保證和監管服務的需求，從而促進對體內外包服務的需求增加。 FDA核准的嚴格流程以及歐盟地區的監管變化預計將使歐洲的核准流程複雜化。這些都是促使製藥公司境外外包到新興國家的主要因素。

COVID-19 大流行最初對臨床試驗行業產生了負面影響，但體內 CRO 市場也是如此。生物製藥產業將重點轉向開發針對 COVID-19 的疫苗和治療方法，這產生了意想不到的後果，可能會擾亂其他疾病的臨床試驗。細胞和基因治療行業的公司面臨的主要挑戰之一是無法在所需的臨床試驗地點及時為患者提供治療。此外，基於細胞的療法的提供在大流行後帶來了一些挑戰。由於擔心 SARS-CoV-2 傳播，尤其是針對弱勢群體，醫院對提供細胞治療服務猶豫不決。由於封鎖和旅行禁令，患者無法前往細胞治療中心。

此外，主要參與企業正在參與併購、夥伴關係、協議、聯盟和服務發布等策略，以擴大其全球足跡和服務/產品系列。例如，2023年4月，PsychoGenics, Inc.宣布推出eCube，這是一個藥理學腦電圖平台，旨在增強表現型藥物發現。同樣，2023年2月，百奧賽圖宣布推出Nano 100計劃，開發100多種針對特定標靶的全人奈米抗體藥物。這項工作將百奧賽圖專有的 RenNano（一種能夠產生完全人類奈米抗體的小鼠模型）與先進的體外和體內抗體篩檢平台結合。透過利用這些整合技術，百奧賽圖有望促進全人類奈米抗體藥物的廣泛開發。

體內 CRO 市場報告亮點

  • 囓齒類動物的需求量一直很大，因為它們在基因上​​與人類相似。由於其體型小、生命週期短、易於維護和遺傳資源豐富，它也是體內 CRO 研究最普遍的動物物種。
  • 小分子領域在體內 CRO 市場中佔據主導地位。這種成長是由候選藥物開發中對小分子的需求所推動的。此外，小分子在小劑量下具有較高的治療功效，這正在推動該領域的成長。
  • 腫瘤學領域在 In Vivo CRO 的全球市場中佔據主導地位，2024 年佔 29.02% 的銷售佔有率。成長的主要促進因素包括癌症負擔的增加、對新基因療法的需求激增以及癌症免疫療法的臨床前測試。據美國基因與細胞治療協會稱，大約 97% 的 CAR T 細胞療法正在針對癌症適應症進行開發。
  • 由於各種針對腦部疾病的模型為基礎的臨床實驗藥物的功效，中樞神經系統疾病領域預計將出現最快的成長。
  • 由於根據特定指南進行的標準化測試的增加，GLP 毒理學領域在 2024 年以最大的收益佔有率佔據市場主導地位。
  • 2024年，北美在體內CRO市場中佔據最大收益佔有率，達到50.0%。該地區的成長歸因於成熟市場參與者的存在、各種疾病負擔的增加以及該地區對 CRO 的需求不斷成長。其他成長要素包括研發活動、臨床前試驗和市場參與者創新的增加。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章體內 CRO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 體內 CRO 市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章體內 CRO 市場：模態估計與趨勢分析

  • 在 Vivo CRO 市場中，按模式：細分儀表板
  • Vivo CRO 市場按模式：波動分析
  • 按方式分類，2018-2030
  • 小分子
    • 小分子市場，2018-2030
  • 高分子
    • 高分子市場，2018-2030
    • 細胞/基因治療
    • RNA療法
    • 其他

第5章體內CRO市場：模型類型估計與趨勢分析

  • 在 Vivo CRO 市場中，按模型類型：細分儀表板
  • 在 Vivo CRO 市場中，依模型類型：變異分析
  • 按車型類型，2018-2030
  • 基於囓齒動物的
    • 囓齒動物市場，2018-2030
    • 大鼠模型
    • 小鼠模型
    • 其他
  • 不囓齒動物為基礎
    • 非囓齒動物市場，2018-2030

第6章體內CRO市場：適應症估計與趨勢分析

  • 在 Vivo CRO 市場中，按指示：細分儀表板
  • 在 Vivo CRO 市場中，依適應症分類：變異分析
  • 按跡象顯示，2018-2030
  • 自體免疫/發炎性疾病
    • 自體免疫疾病/發炎性疾病市場，2018-2030
    • 類風濕性關節炎
    • 多發性硬化症
    • 骨關節炎
    • 大腸激躁症
    • 其他
  • 疼痛管理
    • 疼痛管理市場，2018-2030
    • 慢性疼痛
    • 急性疼痛
  • 腫瘤學
    • 腫瘤市場，2018-2030
    • 血癌
    • 固態腫瘤
    • 其他
  • 中樞神經系統症狀
    • 中樞神經系統疾病市場，2018-2030
    • 癲癇
    • 帕金森氏症
    • 亨丁頓舞蹈症
    • 中風
    • 肌肉萎縮症
    • 阿茲海默症
    • 腦外傷
    • 肌萎縮側索硬化症 (ALS)
    • 脊髓性肌肉萎縮症
    • 肌肉再生
    • 其他神經發育障礙
  • 糖尿病
    • 糖尿病市場，2018-2030
  • 肥胖
    • 肥胖市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第7章體內CRO市場：GLP類型估計與趨勢分析

  • 在體內 CRO 市場，按 GLP 類型：細分儀表板
  • Vivo CRO 市場，依 GLP 類型：波動分析
  • 依 GLP 類型，2018-2030
  • 非GLP
    • 非 GLP 市場，2018-2030
  • GLP毒理學
    • 基於 GLP 毒理學的市場，2018-2030

第8章體內 CRO 市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場簡介
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
  • 2023/24 年企業市場佔有率分析
  • 公司簡介
    • IQVIA Inc
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research（I）Pvt Ltd

第10章主要建議

Product Code: GVR-1-68038-011-8

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

  • The rodent-based segment held the largest revenue share of 81.95% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
  • The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
  • The oncology segment dominated the global in vivo CRO market and accounted for a revenue share of 29.02% in 2024, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
  • The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
  • The GLP toxicology segment dominated the market with the largest revenue share in 2024 owing to the increasing number of standardized studies conducted according to specific guidelines
  • North America held the largest revenue share of 50.0% in in-vivo CRO market in 2024. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Modality
    • 1.2.2. Model Type
    • 1.2.3. Indication
    • 1.2.4. GLP Type
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Changing regulatory landscape
      • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
      • 3.2.1.3. Rising demand for advanced products
      • 3.2.1.4. Implementation of international standards by contract manufacturers
      • 3.2.1.5. Rising price competition and requirement to reduce cost
      • 3.2.1.6. Increasing complexity concerning product design and engineering
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Countries
      • 3.2.2.3. Regulatory And Legal Compliance
      • 3.2.2.4. Contractual Obligation
  • 3.3. In Vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis

  • 4.1. In Vivo CRO Market, By Modality: Segment Dashboard
  • 4.2. In Vivo CRO Market, By Modality: Movement Analysis
  • 4.3. In Vivo CRO Market Estimates & Forecasts, By Modality, 2018 - 2030
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market, 2018 to 2030 (USD Million)
    • 4.5.2. Cell & Gene Therapy
      • 4.5.2.1. Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.2. CAR T-cell therapies
        • 4.5.2.2.1. CAR T-Cell Therapies Market, 2018 to 2030 (USD Million)
      • 4.5.2.3. CAR-NK cell therapy
        • 4.5.2.3.1. CAR-NK Cell Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.4. TCR-T cell therapy
        • 4.5.2.4.1. TCR-T Cell Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.5. Other Cell & Gene Therapy
        • 4.5.2.5.1. Other Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.3. RNA Therapy
      • 4.5.3.1. RNA Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. In Vivo CRO Market, By Model Type: Segment Dashboard
  • 5.2. In Vivo CRO Market, By Model Type: Movement Analysis
  • 5.3. In Vivo CRO Market Estimates & Forecasts, By Model Type, 2018 - 2030
  • 5.4. Rodent based
    • 5.4.1. Rodent based Market, 2018 to 2030 (USD Million)
    • 5.4.2. Rat Models
      • 5.4.2.1. Rat Models Market, 2018 to 2030 (USD Million)
    • 5.4.3. Mice Models
      • 5.4.3.1. Mice Models Market, 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others Market, 2018 to 2030 (USD Million)
  • 5.5. Non-Rodent based
    • 5.5.1. Non-Rodent based Market, 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

  • 6.1. In Vivo CRO Market, By Indication: Segment Dashboard
  • 6.2. In Vivo CRO Market, By Indication: Movement Analysis
  • 6.3. In Vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 6.4. Autoimmune/inflammation conditions
    • 6.4.1. Autoimmune/inflammation conditions Market, 2018 to 2030 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome
      • 6.4.5.1. Irritable Bowel Syndrome Market, 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market, 2018 to 2030 (USD Million)
  • 6.5. Pain management
    • 6.5.1. Pain management Market, 2018 to 2030 (USD Million)
    • 6.5.2. Chronic pain
      • 6.5.2.1. Chronic pain Market, 2018 to 2030 (USD Million)
    • 6.5.3. Acute pain
      • 6.5.3.1. Acute pain Market, 2018 to 2030 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market, 2018 to 2030 (USD Million)
    • 6.6.2. Blood cancer
      • 6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
    • 6.6.3. Solid tumor
      • 6.6.3.1. Solid Tumor Market, 2018 to 2030 (USD Million)
      • 6.6.3.2. Syngeneic model
        • 6.6.3.2.1. Syngeneic Model Market, 2018 to 2030 (USD Million)
      • 6.6.3.3. Patient derived xenograft
        • 6.6.3.3.1. Patient Derived Xenograft Market, 2018 to 2030 (USD Million)
      • 6.6.3.4. Xenograft
        • 6.6.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market, 2018 to 2030 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
    • 6.7.3. Parkinson's disease
      • 6.7.3.1. Parkinson's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.4. Huntington's disease
      • 6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
    • 6.7.6. Muscular Dystrophy
      • 6.7.6.1. Muscular Dystrophy Market, 2018 to 2030 (USD Million)
    • 6.7.7. Alzheimer's Disease
      • 6.7.7.1. Alzheimer's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.8. Traumatic brain injury
      • 6.7.8.1. Traumatic Brain Injury Market, 2018 to 2030 (USD Million)
    • 6.7.9. Amyotrophic lateral sclerosis (ALS)
      • 6.7.9.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
    • 6.7.10. Spinal Muscular Atrophy
      • 6.7.10.1. Spinal Muscular Atrophy Market, 2018 to 2030 (USD Million)
    • 6.7.11. Muscle regeneration
      • 6.7.11.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
    • 6.7.12. Other Neurodevelopment Disorders
      • 6.7.12.1. Other Neurodevelopment Disorders Market, 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market, 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

  • 7.1. In Vivo CRO Market, By GLP Type: Segment Dashboard
  • 7.2. In Vivo CRO Market, By GLP Type: Movement Analysis
  • 7.3. In Vivo CRO Market Estimates & Forecasts, By GLP Type, 2018 - 2030
  • 7.4. Non GLP
    • 7.4.1. Non GLP Market, 2018 to 2030 (USD Million)
  • 7.5. GLP Toxicology
    • 7.5.1. GLP Toxicology based Market, 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. U.S
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Share Analysis, 2023/24
  • 9.3. Company Profiles
    • 9.3.1. IQVIA Inc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Crown Bioscience
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Taconic Biosciences, Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. PsychoGenics Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Evotec
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Janvier Labs
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Biocytogen
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. GemPharmatech
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Charles River Laboratories
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Icon Plc
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Labcorp Drug Development
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Parexel International Corporation
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. SMO Clinical Research (I) Pvt Ltd
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives

Chapter 10 Key Recommendations

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global In Vivo CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 5 Global In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 6 Global In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 7 Global In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 8 North America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 10 North America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 11 North America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 12 North America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 15 U.S. In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 16 U.S. In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 17 Canada In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 18 Canada In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 19 Canada In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 20 Canada In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 21 Mexico In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 23 Mexico In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 24 Mexico In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 25 Europe In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 26 Europe In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 27 Europe In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 28 Europe In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Europe In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 30 UK In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 31 UK In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 32 UK In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 33 UK In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 34 Germany In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 35 Germany In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 36 Germany In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 37 Germany In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 38 France In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 39 France In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 40 France In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 41 France In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 42 Italy In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 43 Italy In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 44 Italy In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 45 Italy In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 46 Spain In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 47 Spain In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 48 Spain In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 49 Spain In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 50 Denmark In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 52 Denmark In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 53 Denmark In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 54 Sweden In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 56 Sweden In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 57 Sweden In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 58 Norway In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 59 Norway In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 60 Norway In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 61 Norway In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 67 Japan In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 68 Japan In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 69 Japan In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 70 Japan In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 71 China In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 72 China In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 73 China In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 74 China In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 75 India In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 76 India In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 77 India In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 78 India In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 79 South Korea In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 80 South Korea In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 81 South Korea In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 82 South Korea In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 83 Australia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 84 Australia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 85 Australia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 86 Australia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 87 Thailand In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 88 Thailand In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 89 Thailand In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 90 Thailand In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 91 Latin America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 93 Latin America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 94 Latin America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 Latin America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 96 Brazil In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 97 Brazil In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 98 Brazil In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 99 Brazil In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 102 Argentina In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 103 Argentina In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East and Africa In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East and Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 106 Middle East and Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 107 Middle East and Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 108 Middle East and Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 109 South Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 111 South Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 112 South Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 117 UAE In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 118 UAE In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 119 UAE In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 120 UAE In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 123 Kuwait In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 124 Kuwait In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 In Vivo CRO Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 Parent Market Analysis
  • Fig. 9 Service/Commodity Flow Analysis
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Model Sizing & Forecasting
  • Fig. 12 Market formulation & validation
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market analysis, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 In vivo CRO market dynamics
  • Fig. 19 FDA expedited approval pathway
  • Fig. 20 Porter's Five Forces Analysis
  • Fig. 21 SWOT analysis by factor (political, legal, economic, social, environmental, and technological)
  • Fig. 22 Companies With Affected Trials, By Size
  • Fig. 23 Affected Trials, By Study Phase
  • Fig. 24 Clinical trial scenario (As of January 2023/24)
  • Fig. 25 In vivo CRO market model type outlook: Segment dashboard
  • Fig. 26 In vivo CRO Market, by model type segment: Market Share, 2024 & 2030
  • Fig. 27 Rodent-based market, 2018 - 2030 (USD Million)
  • Fig. 28 Rat model market, 2018 - 2030 (USD Million)
  • Fig. 29 Mice model market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Non rodent-based market, 2018 - 2030 (USD Million)
  • Fig. 32 In vivo CRO market, by indication segment: Market Share, 2024 & 2030
  • Fig. 33 Autoimmune/inflammatory conditions market, 2018 - 2030 (USD Million)
  • Fig. 34 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 35 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 36 Osteoarthritis market, 2018 - 2030 (USD Million)
  • Fig. 37 Irritable bowel syndrome market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Pain management market, 2018 - 2030 (USD Million)
  • Fig. 40 Chronic pain market, 2018 - 2030 (USD Million)
  • Fig. 41 Acute pain market, 2018 - 2030 (USD Million)
  • Fig. 42 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 43 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 44 Solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 45 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 46 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 47 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 48 Others oncology types market, 2018 - 2030 (USD Million)
  • Fig. 49 CNS conditions market, 2018 - 2030 (USD Million)
  • Fig. 50 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 51 The Parkinson's development pipeline by phase
  • Fig. 52 Parkinson's disease market, 2018 - 2030 (USD Million)
  • Fig. 53 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 54 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 55 Traumatic brain injury market, 2018 - 2030 (USD Million)
  • Fig. 56 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • Fig. 57 Muscle regeneration market, 2018 - 2030 (USD Million)
  • Fig. 58 Alzheimer's development pipeline, by phase
  • Fig. 59 Alzheimer's development pipeline, by disease severity
  • Fig. 60 Alzheimer's disease market, 2018 - 2030 (USD Million)
  • Fig. 61 Spinal muscular atrophy market, 2018 - 2030 (USD Million)
  • Fig. 62 Muscular dystrophy market, 2018 - 2030 (USD Million)
  • Fig. 63 Neurodevelopment disorders market, 2018 - 2030 (USD Million)
  • Fig. 64 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 65 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 66 Others market, 2018 - 2030 (USD Million)
  • Fig. 67 In Vivo CRO Market Modality Type Outlook:Segment dashboard
  • Fig. 68 In Vivo CRO Market, By Modality Type Segment: Market Share, 2024 & 2030
  • Fig. 69 Large molecule market, 2018 - 2030 (USD Million)
  • Fig. 70 Cell and gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 71 CAR-T cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 72 CAR-NK cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 73 TCR-T cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 74 Other market, 2018 - 2030 (USD Million)
  • Fig. 75 RNA therapy market, 2018 - 2030 (USD Million)
  • Fig. 76 Others market, 2018 - 2030 (USD Million)
  • Fig. 77 Small molecules market, 2018 - 2030 (USD Million)
  • Fig. 78 In Vivo CRO Market GLP Type Outlook: Segment dashboard
  • Fig. 79 In Vivo CRO Market, By GLP Type Segment: Market Share, 2024 & 2030
  • Fig. 80 GLP Toxicology Market, 2018 - 2030 (USD Million)
  • Fig. 81 Non-GLP Market, 2018 - 2030 (USD Million)
  • Fig. 82 In vivo CRO market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 83 Regional market share analysis, 2024 & 2030
  • Fig. 84 Regional marketplace: key takeaways
  • Fig. 85 Regional marketplace: key takeaways
  • Fig. 86 North America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 U.S. in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Canada in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Mexico in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Europe in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Germany in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UK in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 France in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Spain in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Denmark in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Sweden in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Asia Pacific in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key Country Dynamics
  • Fig. 112 Japan in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key Country Dynamics
  • Fig. 114 China In vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key Country Dynamics
  • Fig. 116 India in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Key Country Dynamics
  • Fig. 118 Australia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key Country Dynamics
  • Fig. 120 South Korea in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamic
  • Fig. 122 Thailand in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Latin America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Key country dynamics
  • Fig. 125 Brazil in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 126 Key country dynamics
  • Fig. 127 Argentina in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 128 MEA in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 129 Key country dynamics
  • Fig. 130 South Africa in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 131 Key country dynamics
  • Fig. 132 Saudi Arabia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 133 Key country dynamics
  • Fig. 134 UAE in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 135 Key country dynamics
  • Fig. 136 Kuwait in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 137 Key company categorization
  • Fig. 138 Company market position analysis
  • Fig. 139 In Vivo CRO Market Share Analysis, 2023
  • Fig. 140 Strategic framework